SUBSTRATE-SELECTIVE INHIBITION BY VERAPAMIL AND DILTIAZEM - DIFFERENTIAL DISPOSITION OF ANTIPYRINE AND THEOPHYLLINE IN HUMANS
- 1 March 1988
- journal article
- research article
- Vol. 244 (3) , 994-999
Abstract
Antipyrine and theophylline disposition was studied in healthy volunteer subjects in the control state while the subjects were taking verapamil (120 mg) orally four times daily or diltiazem (120 mg) orally three times daily. Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P < .01; diltiazem, 41.7 to 29.9 ml/min, P < .01), resulting in prolonged antipyrine half-life with no change in distribution volume. Fractional clearances of urinary antipyrine metabolites 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, norantipyrine and unchanged antipyrine were differentially changed by verapamil and diltiazem treatment. With verapamil treatment, 4-hydroxyantipyrine and norantipyrine fractional clearance were markedly decreased, with 3-hydroxymethylantipyrine slightly decreased and antipyrine unchanged. With diltiazem treatment, 3-hydroxymethylantipyrine was decreased, with no significant change in 4-hydroxyantipyrine, norantipyrine or antipyrine. Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P < .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment. Fractional clearances of urinary theophylline metabolites 3-methylxanthine, 1-methyluricacid, 1,3-dimethyluricacid and unchanged theophylline reflected the differential plasma theophylline clearance. During verapamil treatment, 3-methylxanthine and 1,3-dimethyluricacid fractional clearances were decreased, with no change in 1-methyluricacid or theophylline. During diltiazem treatment, 1,2-dimethyluricacid fractional clearance was slightly decreased, and 3-methylxanthine, 1-methyluricacid and theophylline were unchanged. These findings suggest tht verapamil and diltiazem exhibit selectivity in their inhibitory effects on cytochrome P-450 species, the enzymes of biotransformation for antipyrine and theophylline, and that such selectivity may result in differential capacity for inhibiting biotransformation of theophylline, a drug extensively used as a bronchodilator.This publication has 14 references indexed in Scilit:
- COMPARISON OF MONOOXYGENASE ACTIVITIES AND CYTOCHROME-P-450 ISOZYME CONCENTRATIONS IN HUMAN-LIVER MICROSOMES1986
- The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.British Journal of Clinical Pharmacology, 1986
- Human-liver cytochromes P-450 involved in polymorphisms of drug oxidationXenobiotica, 1986
- Polymorphisms of antipyrine and theophylline metabolism in man: Molecular and clinical implicationsXenobiotica, 1986
- Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamilBiochemical Pharmacology, 1985
- Polymorphism of theophylline metabolism in man.Journal of Clinical Investigation, 1985
- ISOZYME SELECTIVITY OF THE INHIBITION OF RAT-LIVER CYTOCHROMES P-450 BY CHLORAMPHENICOL INVIVO1985
- Theophylline ReassessedAnnals of Internal Medicine, 1984
- Multiple cytochromes P-450 are translated from multiple mRNAsBiochemistry, 1983
- Antipyrine metabolism in the rat by three hepatic monooxygenasesLife Sciences, 1980